#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 13°C Thursday 13 May 2021
Advertisement

Novavax Covid-19 vaccine shows 89% efficacy in late-stage clinical trials

More than 15,000 people were included in the Phase 3 UK trial.

Image: Shutterstock/Viacheslav Lopatin

AN EXPERIMENTAL COVID-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.

The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.

The European Commission had exploratory talks with the company last month to potentially purchase at least 100 million doses for EU member states. 

The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.

“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against Covid-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” said Stanley Erck, the biotechnology firm’s president and chief executive.

The trial was carried out in conjunction with the UK Government’s Vaccine Taskforce, with its chairman Clive Dix saying in a statement: “These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.

“The efficacy shown against the emerging variants is also extremely encouraging. This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”

The vaccine was shown to be less effective against the South African strain of the virus, however. 

In the South African arm of the trial, where most cases of Covid-19 were the South African strain, the jab was 60% effective in preventing mild, moderate and severe coronavirus among those without HIV.

Including the HIV positive participants, whose immune systems are compromised, overall the protection was just over 49%.

Although the UK has 60 million doses on order, it will need to be approved by the Medicines and Healthcare products Regulatory Agency.

Prime Minister Boris Johnson has said it is “good news” that the experimental coronavirus vaccine from Novavax appears to offer strong protection in late-stage UK and South Africa studies.

Health Secretary Matt Hancock said the NHS stands ready to roll out the Novavax vaccine if it is approved by the medicines regulator.

He said: “This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.

“I’m proud the UK is at the forefront of another medical breakthrough and I want to thank the brilliant scientists and researchers, as well as the tens of thousands of selfless volunteers who took park in clinical trials.

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

“The NHS stands ready to roll this vaccine out as quickly as possible to those most at risk if it is authorised.”

Vaccines Minister Nadhim Zahawi added: “Having taken part in Novavax’s vaccine trial myself, I am particularly thrilled to see such positive results. I want to thank the thousands of trial volunteers, without whom these results would not have been possible.

“It will now be for the regulator to do its crucial work in assessing the efficacy and safety of this vaccine, but if approved it will be a further boost to our vaccination programme.”

About the author:

Press Association

Read next:

COMMENTS (13)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

    Leave a commentcancel